^
Association details:
| Biomarker: | FGFR3-TACC3 fusion |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | LY3076226 (Microtubule inhibitor, FGFR3-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LY3076226, a novel anti-FGFR3 antibody drug conjugate exhibits potent and durable anti-tumor activity in tumor models harboring FGFR3 mutations or fusions
Excerpt:
In vivo studies with LY3076226 demonstrated robust antitumor efficacy resulting in tumor stasis or partial or complete tumor responses after 4 weekly doses at 5 mg/kg in bladder cancer cell lines: SW780, RT112 and UMUC-14 that harbor FGFR3-BAIAP2L1, FGFR3-TACC3 fusion or S249C mutation, respectively.
DOI:
https://doi.org/10.1158/1538-7445.AM2019-4835
